Agios Pharmaceuticals to present AG-221 Phase 1 study results at EHA meeting

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that new clinical data from the Phase 1 study of AG-221, an orally available, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19^th Congress of the European Hematology Association (EHA) taking place June 12 -15, 2014 in Milan, Italy.

"We look forward to sharing these new clinical data with the medical community during the late-breaker session at EHA," said David Schenkein, M.D., chief executive officer of Agios. "The data build upon the AG-221 preliminary results we presented last month at the American Association for Cancer Research (AACR) Annual Meeting, and include additional patients from existing and new dose cohorts."

Title: A Phase I Study of AG-221, a First in Class, Potent Inhibitor of the IDH2-Mutant Protein, in Patients with IDH2 Mutant Positive Advanced Hematologic Malignancies

Presentation time: Saturday, June 14 at 1:30 p.m. CEST

Session title: Late breaking1

Presenter: Stephane De Botton, M.D., Institut de Cancerologie Gustave Roussy, Villejuif, France

Abstract code: LB2434

Conference Call Information

Agios will host a conference call and webcast on Monday, June 16, 2014, at 8:30 a.m. EDT to review the clinical data presented at EHA from the ongoing Phase 1 study of AG-221.